{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:54:10Z","timestamp":1793861650767,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Vaccine-induced immune thrombocytopenia and thrombosis (VITT) was first described after administration of adenovirus-vectored COVID-19 vaccines including Ad26.COV2.S and ChAdOx1 nCoV-19. It is not known if the clinical characteristics and outcomes of VITT after Ad26.COV2.S and ChAdOx1 nCoV-19 vaccination are different. We assessed demographic and clinical characteristics, laboratory findings and outcomes in patients with VITT after each vaccine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Spontaneous postmarketing reports of VITT after Ad26.COV2.S were identified from Janssen\u2019s Global Safety Database and classified using NICE criteria (<jats:italic>n<\/jats:italic>\u2009=\u200986). Cases after ChAdOx1 nCoV-19 were identified from a published case series (<jats:italic>n<\/jats:italic>\u2009=\u2009220). The analysis is descriptive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median age of patients with definite\/probable VITT after Ad26.COV2.S or ChAdOx1 nCoV-19 vaccination is 43 and 48 years, respectively. Median time-to-onset is 11 days and 14 days post-vaccination, cerebral venous thrombosis (CVT) is present in 50.6% and 50%, and mortality is 30% and 22% of patients, respectively. Women make up 55.3% of cases after Ad26.COV2.S and 55% after ChAdOx1 nCoV-19, 74%\/60% of CVT cases and 68%\/62.5% of deaths. Patients present with severe thrombocytopenia, grossly elevated D-dimer, and most test positive for anti-platelet factor-4 antibodies. Patients with preexisting rare autoimmune diseases are observed despite the small sample sizes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Within the limitations of the data, our study finds no strong evidence for a clinically relevant difference in VITT occurring after Ad26.COV2.S or ChAdOx1 nCoV-19. Observed differences in some parameters likely result from the demographic of the populations vaccinated, and the situational and reporting differences in how, when, and where patients were identified and treated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s43856-025-00891-x","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T17:51:49Z","timestamp":1746899509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9865-3952","authenticated-orcid":false,"given":"Rian","family":"Van Rampelbergh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0840-5614","authenticated-orcid":false,"given":"Sue","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Anaya-Velarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalija","family":"van Paassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Tatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ruiz-Gui\u00f1az\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Baumgardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Oriol Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Praet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendy","family":"Kristyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-0260","authenticated-orcid":false,"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","volume":"385","author":"S Pavord","year":"2021","unstructured":"Pavord, S. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N. Engl. J. Med. 385, 1680\u20131689 (2021).","journal-title":"N. Engl. J. Med."},{"key":"891_CR2","unstructured":"Chen, R. & Buttery Monash, J. Interim case definition of thrombosis with thrombocytopenia syndrome (TTS) v10.16.4 November 11, 2021. https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/11\/TTS-Updated-Brighton-Collaboration-Case-Defintion-Draft-Nov-11-2021.pdf. Accessed October 22, 2022."},{"key":"891_CR3","unstructured":"Shimabukuro, T. Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention; Update: thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-05-12\/07-COVID-Shimabukuro-508.pdf Accessed March 02, 2022 (2021)."},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"n2195","DOI":"10.1136\/bmj.n2195","volume":"375","author":"S Pavord","year":"2021","unstructured":"Pavord, S., Hunt, B. J., Horner, D., Bewley, S. & Karpusheff, J. Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance. BMJ 375, n2195 (2021).","journal-title":"BMJ"},{"key":"891_CR5","unstructured":"American Society of Hematology. Vaccine-induced immune thrombotic thrombocytopenia. 2022. https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia. Accessed March 2, 2022."},{"key":"891_CR6","unstructured":"British Society for Haematology. Guidance produced by the Expert Haematology Panel (EHP) focussed on vaccine induced thrombosis and thrombocytopenia (VITT). https:\/\/b-s-h.org.uk\/about-us\/news\/guidance-produced-by-the-expert-haematology-panel-ehp-focussed-on-vaccine-induced-thrombosis-and-thrombocytopenia-vitt\/ Accessed March 2, 2022 (2021)."},{"key":"891_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.7326\/M21-4502","volume":"175","author":"I See","year":"2022","unstructured":"See, I. et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann. Intern. Med. 175, 513\u2013522 (2022).","journal-title":"Ann. Intern. Med."},{"key":"891_CR8","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.7861\/clinmed.2021-0488","volume":"21","author":"T Chevassut","year":"2021","unstructured":"Chevassut, T., Hunt, B. J. & Pavord, S. VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme. Clin. Med. 21, e600\u2013e602 (2021).","journal-title":"Clin. Med."},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3324\/haematol.2021.280154","volume":"107","author":"S Michalik","year":"2022","unstructured":"Michalik, S. et al. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica 107, 947\u2013957 (2022).","journal-title":"Haematologica"},{"key":"891_CR10","unstructured":"European Medicines Agency. Committee for Medical Products for Human Use. Vaxzevria EMEA-H-A-5(3)-1507 assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/use-vaxzevria-prevent-covid-19-article-53-procedure-final-assessment-report_en.pdf Accessed March 2, 2022 (2021)."},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.vaccine.2024.01.045","volume":"42","author":"L Schonborn","year":"2024","unstructured":"Schonborn, L. et al. Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 42, 1799\u20131811 (2024).","journal-title":"Vaccine"},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","volume":"596","author":"A Huynh","year":"2021","unstructured":"Huynh, A., Kelton, J. G., Arnold, D. M., Daka, M. & Nazy, I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 596, 565\u2013569 (2021).","journal-title":"Nature"},{"key":"891_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminhematol.2022.02.004","volume":"59","author":"A Greinacher","year":"2022","unstructured":"Greinacher, A. et al. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol. 59, 97\u2013107 (2022).","journal-title":"Semin Hematol."},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1182\/bloodadvances.2022007336","volume":"7","author":"A Huynh","year":"2023","unstructured":"Huynh, A. et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv. 7, 246\u2013250 (2023).","journal-title":"Blood Adv."},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2207566","volume":"388","author":"AR Falsey","year":"2023","unstructured":"Falsey, A. R. et al. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N. Engl. J. Med. 388, 609\u2013620 (2023).","journal-title":"N. Engl. J. Med."},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N. Engl. J. Med. 385, 1078\u20131090 (2021).","journal-title":"N. Engl. J. Med."},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"e222940","DOI":"10.1001\/jamanetworkopen.2022.2940","volume":"5","author":"TM Tu","year":"2022","unstructured":"Tu, T. M. et al. Incidence of cerebral venous thrombosis following SARS-CoV-2 infection vs mRNA SARS-CoV-2 vaccination in Singapore. JAMA Netw. Open 5, e222940 (2022).","journal-title":"JAMA Netw. Open"},{"key":"891_CR18","unstructured":"Committee for Medicinal Products for Human Use. Assessment report. COVID-19 Vaccine Janssen 2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf. Accessed 31 March 2024."},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1148\/radiol.220365","volume":"305","author":"P Rogers","year":"2022","unstructured":"Rogers, P. et al. Thrombus distribution in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Radiology 305, 590\u2013596 (2022).","journal-title":"Radiology"},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"e12572","DOI":"10.1002\/rth2.12572","volume":"5","author":"A Berezne","year":"2021","unstructured":"Berezne, A. et al. Deterioration of vaccine-induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay. Res. Pract. Thromb Haemost. 5, e12572 (2021).","journal-title":"Res. Pract. Thromb Haemost."},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jth.15572","volume":"20","author":"A Greinacher","year":"2022","unstructured":"Greinacher, A. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. J. Thromb. Haemost. 20, 149\u2013156 (2022).","journal-title":"J. Thromb. Haemost."},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1053\/j.seminhematol.2022.03.002","volume":"59","author":"N Gabarin","year":"2022","unstructured":"Gabarin, N., Arnold, D. M., Nazy, I. & Warkentin, T. E. Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol. 59, 89\u201396 (2022).","journal-title":"Semin Hematol."},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","volume":"33","author":"GS Cooper","year":"2009","unstructured":"Cooper, G. S., Bynum, M. L. & Somers, E. C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 33, 197\u2013207 (2009).","journal-title":"J. Autoimmun."},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","volume":"11","author":"SM Hayter","year":"2012","unstructured":"Hayter, S. M. & Cook, M. C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun. Rev. 11, 754\u2013765 (2012).","journal-title":"Autoimmun. Rev."},{"key":"891_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","volume":"29","author":"WW Eaton","year":"2007","unstructured":"Eaton, W. W., Rose, N. R., Kalaydjian, A., Pedersen, M. G. & Mortensen, P. B. Epidemiology of autoimmune diseases in Denmark. J. Autoimmun. 29, 1\u20139 (2007).","journal-title":"J. Autoimmun."},{"key":"891_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223\u2013243 (1997).","journal-title":"Clin. Immunol. Immunopathol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00891-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T17:51:55Z","timestamp":1746899515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00891-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00891-x","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: R.V.R., L.A.V., V.v.P., K.H., E.T., J.R.G., D.B., V.O.M., N.P., H.K. J.S., M.D., Y.X. and F.S. are or were employees of Janssen Research & Development LLC at time of the study and may hold stock or shares in J.&J. S.P. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}